BTI-320: Completed Phase IIb enrollment

Boston Therapeutics completed enrollment of 24 Type II diabetics who are being treated with metformin in the double-blind, placebo-controlled, 3-way crossover, U.S. Phase IIb SD-002 trial evaluating B...